{"disease":{"id":"locally-advanced-or-metastatic-urothelial-cancer","name":"locally advanced or metastatic urothelial cancer"},"drugs":{"marketed":[{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."},{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Single Agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04527991","title":"Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT04004221","title":"Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}